Related Experiment Video
Updated: Apr 1, 2026
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Diabetic patients and beta-blockers after acute myocardial infarction
1Department of Medicine, University of California, San Diego Medical Center, Veterans Administration Hospital.
Insights
Diabetic patients with acute myocardial infarction may benefit from beta-blocker therapy, showing reduced 1-year mortality compared to those not on beta-blockers. Further randomized studies are needed to confirm these findings for diabetic cardiac survival.
Area of Science:
- Cardiology
- Diabetology
- Pharmacology
Background:
- Diabetic patients face higher mortality rates after acute myocardial infarction (AMI).
- The role of beta-blocker therapy in improving outcomes for diabetic AMI patients remains unclear.
- Previous studies have not definitively established the benefit of beta-blockers in this specific population.
Purpose of the Study:
- To investigate the potential benefit of beta-blocker therapy in diabetic patients following acute myocardial infarction.
- To compare the 1-year mortality rates between diabetic and non-diabetic patients after AMI.
- To assess whether beta-blocker use independently predicts cardiac survival in diabetic patients post-AMI.
Main Methods:
- A large multicentre cohort study involving 2024 patients, including 340 diabetics.
- Analysis of 1-year mortality rates following hospital discharge based on diabetes status and beta-blocker use.
- Multivariate analysis to identify independent predictors of cardiac survival, considering factors like pulmonary congestion.
Main Results:
- Diabetic patients had significantly higher 1-year mortality (17%) compared to non-diabetics (10%) post-discharge.
- Diabetics on beta-blockers showed reduced 1-year mortality (10%) versus those not on beta-blockers (23%).
- Beta-blocker use was an independent predictor of 1-year cardiac survival in diabetics, even those without pulmonary congestion.
Conclusions:
- Beta-blocker therapy may offer a survival benefit for diabetic patients after acute myocardial infarction.
- The observed benefits suggest a potential role for beta-blockers in managing diabetic cardiac patients.
- A prospective, randomized study is required to definitively confirm the efficacy of beta-blockade in this patient group.
Abstract:
Whether diabetic patients may benefit, compared with non-diabetic patients, from beta-blocker therapy following acute myocardial infarction was examined in a large multicentre cohort of 2024 patients, including 340 diabetics, 281 of whom survived hospitalization. One-year mortality following discharge was 17% for diabetics compared with 10% for non-diabetics (P less than 0.001). However, diabetics discharged on beta-blockers had a 1-year mortality of only 10%, compared with 23% for diabetics not on beta-blockers. In non-diabetics, mortality rates were 7% and 13% for those taking and not taking beta-blockers, respectively. Bias in patient selection for beta-blocker therapy might be responsible for the trends exhibited in our population since patients were not randomized to treatment. In diabetics, evidence of pulmonary congestion on X-ray was more prevalent than in non-diabetics; this appeared to be true both for patients taking beta-blockers and for those not taking beta-blockers. However, even in diabetics without evidence of pulmonary congestion on X-ray, 1-year mortality was 7% vs 17% for those with and without beta-blocker therapy, respectively (P less than 0.04). In multivariate analysis, beta-blocker use was an independent predictor of 1-year cardiac survival following hospital discharge for all diabetics, even those without evidence for pulmonary congestion on X-ray, but not for non-diabetics. These data suggest a beneficial effect, but a definitive answer regarding the benefit of beta-blockade in diabetic patients after acute myocardial infarction would require a prospective, randomized study.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:28Antihypertensive Drugs: Types of β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers